| ABHD12 Protein | |
|---|---|
| Protein Name | Alpha/Beta Hydrolase Domain-Containing 12 |
| Encoded by | [ABHD12](/genes/abhd12) |
| UniProt | [Q8N2K0](https://www.uniprot.org/uniprotkb/Q8N2K0/entry) |
| Localization | Endoplasmic reticulum-associated membrane; enriched in [microglia](/cell-types/microglia-neuroinflammation) |
| Enzyme Class | Serine hydrolase / lysophosphatidylserine lipase |
| Key Disease Link | PHARC syndrome (biallelic loss-of-function) |
ABHD12 is a brain-relevant lipid hydrolase that regulates lysophosphatidylserine (lyso-PS) tone and related inflammatory signaling in the central nervous system.[1][2] Its strongest human disease association is PHARC syndrome (polyneuropathy, hearing loss, ataxia, retinitis pigmentosa, cataract), where recessive ABHD12 loss-of-function variants cause progressive neurodegeneration.[1:1] In mechanistic terms, ABHD12 sits at the interface of lipid metabolism, innate immune activation, and neuroinflammatory injury pathways.
ABHD12 belongs to the alpha/beta hydrolase fold family and contains the canonical serine-hydrolase catalytic motif.[2:1] The enzyme is membrane-associated, with topology consistent with activity on membrane phospholipid substrates rather than bulk cytosolic lipid pools.[2:2][3]
Key biochemical points:
Lyso-PS is not only a membrane intermediate; it is also an immune-active signaling lipid. ABHD12 constrains lyso-PS accumulation, thereby limiting excessive inflammatory activation in neural immune niches.[2:4][3:2]
ABHD12 is enriched in microglial compartments, and its deficiency shifts microglia toward pro-inflammatory programs in preclinical systems.[5][6] This places ABHD12 in a mechanistic axis connecting lipid catabolism to immune-mediated neuronal vulnerability.
ABHD12 can be interpreted as a "lipid brake" on inflammatory amplification. When that brake fails, cumulative lipid-immune dysregulation can propagate to cerebellar, retinal, and peripheral neural phenotypes, matching PHARC clinical anatomy.[1:2][2:5]
Human genetics established ABHD12 loss as causative for PHARC.[1:3] The syndrome's multisystem neurodegenerative pattern aligns with disrupted lipid signaling and chronic neuroimmune stress, rather than a single-neuron-subtype lesion.
Although PHARC is rare, ABHD12 biology maps onto common seen across tauopathy, alpha-synuclein pathology, and neuroinflammation:
This does not prove ABHD12 is a primary driver in common disorders, but it supports ABHD12 as a mechanistically plausible modifier node.
For PHARC-like ABHD12 deficiency states, therapeutic logic favors restoration (gene/protein function rescue), not inhibition.
For other indications, ABHD12 inhibition has been used as a pharmacologic probe (for example DO264) to interrogate immune-lipid signaling and ferroptosis-linked biology.[7]
Fiskerstrand T, et al. Mutations in ABHD12 cause the neurodegenerative disease PHARC: an inborn error of endocannabinoid metabolism. American Journal of Human Genetics. 2010. ↩︎ ↩︎ ↩︎ ↩︎
Blankman JL, et al. ABHD12 controls brain lysophosphatidylserine pathways that are deregulated in a murine model of the neurodegenerative disease PHARC. Proceedings of the National Academy of Sciences USA. 2013. ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎
Kamat SS, et al. Immunomodulatory lysophosphatidylserines are regulated by ABHD16A and ABHD12 interplay. Nature Chemical Biology. 2015. ↩︎ ↩︎ ↩︎ ↩︎
Wang C, et al. A chemical-genetic screen identifies ABHD12 as an oxidized-phosphatidylserine lipase. Nature Chemical Biology. 2019. ↩︎ ↩︎
Cuyvers K, et al. Mapping the neuroanatomy of ABHD16A, ABHD12, and lysophosphatidylserines provides new insights into the pathophysiology of PHARC. Brain Pathology. 2020. ↩︎ ↩︎
Arcourt A, et al. The loss of enzymatic activity of the PHARC-associated lipase ABHD12 results in increased phagocytosis that causes neuroinflammation. GLIA. 2022. ↩︎ ↩︎
Ogasawara D, et al. Selective blockade of the lyso-PS lipase ABHD12 stimulates immune responses in vivo. Nature Chemical Biology. 2019. ↩︎